Breast Cancer : Targets and Therapy最新文献

{"title":"Risk Factors and Prognosis Analysis of Infiltrating Micropapillary Carcinoma of Breast: A Retrospective Study.","authors":"Pengfei He, Yupeng Sha, Yige Lu, Tong Li, Xiaoming Li, Yixin Liu, Hui Pang, Jiguang Han, Quan Yuan","doi":"10.2147/BCTT.S612948","DOIUrl":"10.2147/BCTT.S612948","url":null,"abstract":"<p><strong>Background: </strong>Invasive micropapillary carcinoma (IMPC) is a rare breast cancer subtype with high invasiveness and lymphovascular/lymph node metastasis. While poor prognosis is reported, long-term survival and roles of molecular subtyping/laboratory markers remain unclear.</p><p><strong>Methods: </strong>We retrospectively analyzed 653 IMPC patients from a Chinese center (as of December 2024). Kaplan-Meier estimated progression-free survival (PFS) and overall survival (OS); Cox regression assessed prognostic factors.</p><p><strong>Results: </strong>Among 653 patients with IMPC, the molecular subtype distribution was as follows: HR+/HER2-, 48.2%; HR+/HER2+, 35.4%; HR-/HER2-, 11.0%; and HR-/HER2+, 5.4%. Most patients had T1-2 disease and were postmenopausal. The 3-year and 5-year OS rates were 97.42% and 93.73%, respectively, while the 3-year and 5-year PFS rates were 90.66% and 81.20%, respectively. Kaplan-Meier analysis showed significant differences in PFS among molecular subtypes, but not in OS. In multivariable analysis, the HR+/HER2+ subtype and higher total bilirubin were independently associated with better PFS, whereas higher systemic immune-inflammation index and stage IIIB were associated with worse PFS. Poorer OS was independently associated with advanced stage, no surgery, alcohol consumption history, higher systemic immune-inflammation index, menopausal status, and elevated blood glucose, while mastectomy and endocrine therapy were associated with better OS.</p><p><strong>Conclusion: </strong>IMPC shows favorable OS but requires progression risk monitoring. PFS varied by molecular subtype, while OS did not. Molecular typing, clinical stage, and inflammatory/biochemical markers aid prognosis and personalized treatment.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"612948"},"PeriodicalIF":3.6,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13291655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148326953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Induced Electric Fields Inhibit Breast Cancer Growth and Metastasis and Modulate the Immune Tumor Microenvironment.","authors":"Manish Charan, Travis H Jones, Dinesh K Ahirwar, Nandini Acharya, Vish V Subramaniam, Konstantin Shilo, Ramesh K Ganju, Jonathan W Song","doi":"10.2147/BCTT.S604098","DOIUrl":"10.2147/BCTT.S604098","url":null,"abstract":"<p><strong>Introduction: </strong>Metastatic triple-negative breast cancer (TNBC) remains highly challenging to treat despite advances in oncology. This study investigated whether non-invasive alternating, low-intensity induced electric fields (iEFs) could suppress tumor growth and metastasis while modulating anti-tumor immunity in TNBC.</p><p><strong>Methods: </strong>Orthotopic TNBC mouse models were treated with alternating (100 kHz) and low-intensity (2.7 mV/cm peak), induced electric fields (iEFs), which were delivered non-invasively via a solenoid coil system. Tumor growth and lung metastasis were assessed following treatment. Immune profiling was performed to evaluate changes in T cell states and myeloid cell populations within both primary tumors and metastatic lung tissue.</p><p><strong>Results: </strong>iEF treatment significantly reduced primary tumor growth (n=9) and lung metastases (n=5). Within the tumor microenvironment, iEFs decreased infiltration of immunosuppressive myeloid cells (n=8). In the lung metastatic niche, iEF therapy increased CD8+ T cell abundance while reducing immunosuppressive myeloid populations (n=8). We also observed that iEFs reduced the metastatic potential of cancer cells by inhibiting epithelial-to-mesenchymal transition (n=3).</p><p><strong>Conclusion: </strong>Induced electric field therapy enhances anti-tumor immunity and suppresses metastatic progression in TNBC by enhancing T cell activity and remodeling immunosuppressive myeloid environments. These findings support iEFs as a promising non-invasive immunomodulatory strategy for metastatic TNBC.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"604098"},"PeriodicalIF":3.6,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13282987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148293211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pan-Cancer Analysis of a Depression-Related Gene Signature Identifies an Immunosuppressive Tumor Microenvironment and Links to Immunotherapy Response in Breast Cancer.","authors":"Guanling Chen, Baoliang Yin, Muhammad Khan, Yipeng Yang, Qian Sun, Tingfeng Zhang, Hong Hu, Jie Lin","doi":"10.2147/BCTT.S578930","DOIUrl":"10.2147/BCTT.S578930","url":null,"abstract":"<p><strong>Background: </strong>Depression has been increasingly associated with cancer progression and patient outcomes, yet its molecular and immunological correlates within tumors remain incompletely understood. This study aimed to investigate depression-associated gene signature across cancers and evaluate their relationship with tumor biology, immune microenvironment, and clinical outcomes, with a focus on breast cancer.</p><p><strong>Methods: </strong>A depression-related gene signature comprising 382 genes was obtained from the Molecular Signatures Database and used to compute a DScore via single-sample gene set enrichment analysis (ssGSEA) across over 10,000 tumor samples from 33 cancer types in The Cancer Genome Atlas (TCGA). Tumor microenvironment features were assessed using ESTIMATE and CIBERSORT, and cell-type-specific patterns were evaluated using single-cell RNA sequencing. CACNA1H was validated using qPCR and IHC in breast cancer samples.</p><p><strong>Results: </strong>DScore exhibited tissue-specific patterns across cancers and was elevated in several tumor types, including gastrointestinal, brain, renal, and endocrine malignancies. Higher DScore was associated with older age, advanced stage, and poorer survival across multiple malignancies, including breast, ovarian, uterine, and lung cancers, whereas inverse associations with survival were observed in selected brain, kidney, and endocrine cancers. Higher DScore was further associated with genomic instability, an immunosuppressive tumor microenvironment (TME), and poorer survival across multiple cancers, particularly in breast and ovarian cancers. In breast cancer, this phenotype was characterized by monocytic-lineage enrichment, increased M2 macrophages, and reduced CD8⁺ T-cell infiltration. Consistent with these findings, higher DScore was associated with reduced benefit from immune checkpoint therapy in breast and bladder cancers, with non-responders exhibiting higher DScore predominantly enriched in monocytic-lineage cells. CACNA1H was identified as a depression-related gene correlated with poor prognosis in breast cancer and was validated in independent cohorts.</p><p><strong>Conclusion: </strong>Depression-associated gene expression patterns are linked to tumor biology and immune features across cancers, with particularly strong relevance in breast cancer. These findings highlight the need for further research into how psychological, molecular, and immune factors interact in cancer progression and treatment response.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"578930"},"PeriodicalIF":3.6,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rab1A-Mediated Exosomal Sorting of miR-200c Enhances Breast Cancer Lung Metastasis [Retraction].","authors":"","doi":"10.2147/BCTT.S631806","DOIUrl":"https://doi.org/10.2147/BCTT.S631806","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.2147/BCTT.S400974.].</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"631806"},"PeriodicalIF":3.6,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148275966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2 Heterogeneity in Breast Cancer: Biological Basis, Clinical Implications, and Therapeutic Strategies.","authors":"Hanxiao Shi, Yiqian Feng, Tao Guo, Wenjun Shou, Yuandong Li","doi":"10.2147/BCTT.S612951","DOIUrl":"10.2147/BCTT.S612951","url":null,"abstract":"<p><p>Human epidermal growth factor receptor 2 (HER2) is a key driver of breast cancer and exhibits significant heterogeneity at the temporal, spatial, and molecular levels. This heterogeneity not only complicates HER2 assessment but also significantly impacts the efficacy of targeted therapies, ultimately contributing to drug resistance. This review summarizes current standards for HER2 testing and highlights their inherent limitations. It outlines the multidimensional manifestations of HER2 heterogeneity and examines the underlying biological mechanisms driving this phenomenon. In addition, emerging diagnostic strategies and therapeutic approaches are being developed specifically to address HER2 heterogeneity. The review aims to provide insights for optimizing patient stratification and advancing precision treatment in breast cancer.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"612951"},"PeriodicalIF":3.6,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Willingness to Undergo Corrective Surgery After Breast-Conserving Surgery in Chinese Patients with Breast Deformities: A Single-Center Study.","authors":"Jingyan Zhang, Zejun Wu, Jingyan Gao, Fang Gao, Fan Guo","doi":"10.2147/BCTT.S614465","DOIUrl":"10.2147/BCTT.S614465","url":null,"abstract":"<p><strong>Objective: </strong>To assess willingness to undergo corrective surgery among patients with breast deformities after breast-conserving surgery (BCS) and to identify factors associated with surgical decision-making.</p><p><strong>Methods: </strong>This single-center cross-sectional study included female breast cancer patients who underwent BCS at Shanxi Bethune Hospital between July 2012 and December 2024, completed adjuvant radiotherapy, and had at least one year of follow-up after radiotherapy. Breast deformity was assessed using the Clough classification. A structured questionnaire evaluated perceived breast appearance, satisfaction, appearance-related distress, willingness toward corrective surgery, reasons for refusal, facilitating factors, and information needs. Willingness was defined as patients' self-reported acceptance of considering corrective surgery at the time of the survey, rather than a confirmed operative plan. Associations were assessed using univariate analyses.</p><p><strong>Results: </strong>Among 306 patients with post-BCS breast deformities, 123 (40.2%) expressed willingness to undergo corrective surgery and 183 (59.8%) declined. Surgical willingness showed unadjusted associations with several sociodemographic and clinical characteristics, including residence, income, travel time to medical care, deformity grade, postoperative complications, and recurrence/metastasis status. Among patients declining correction, the most important barriers were concern about complications or reconstruction failure (12.3%), financial burden (12.1%), acceptance of current appearance (11.2%), and reluctance to undergo another surgical procedure (10.0%). Among willing patients, the main facilitators were desire to improve body image/self-confidence (16.0%) and physician recommendation (16.0%).</p><p><strong>Conclusion: </strong>Willingness to undergo corrective surgery after BCS was relatively low and appeared to be shaped by economic burden, risk perception, and appearance-related needs. These findings should be interpreted cautiously because of the single-center cross-sectional design and the absence of multivariable adjustment.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"614465"},"PeriodicalIF":3.6,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemodynamic Inflow-Outflow Profiling as an Integrated DCE-MRI Biomarker for Diagnosis and Risk Stratification in Breast Cancer: A Multicenter Retrospective Study.","authors":"Chenyi Zhou, Yahao Guo, Zhanao Meng, Kunming Wan, Jie Qin, Yanling Wang","doi":"10.2147/BCTT.S563533","DOIUrl":"10.2147/BCTT.S563533","url":null,"abstract":"<p><strong>Background: </strong>Limitations in conventional MRI biomarkers (ADC, DCE-MRI parameters) for characterizing tumor microenvironment heterogeneity necessitate novel approaches integrating vascular remodeling dynamics. We introduce the Intratumoral-Peritumoral Inflow-Outflow (IPIO) model to address these constraints.</p><p><strong>Methods: </strong>This multicenter retrospective study developed and validated a hemodynamics-driven IPIO model using DCE-MRI kinetics in 159 patients (training: n=93; independent validation: n=66). Performance was evaluated for malignancy detection and stratification (invasive grading, molecular subtyping of TNBC, Ki-67 expression, lymph node metastasis) through ROC analysis and correlation studies.</p><p><strong>Results: </strong>IPIO demonstrated robust malignancy discrimination (AUC 0.934, 95% CI: 0.897-0.974; sensitivity 91.7%, specificity 83.3%), significantly outperforming ADC (ΔAUC +0.123, <i>P</i><0.05) and conventional kinetics. For TNBC identification, IPIO achieved an AUC of 0.901 (accuracy 96.4%); for LNM detection, AUC was 0.821 (sensitivity 95.5%); Strong correlations with invasive grade (r=0.548), Ki-67 (r=0.501), and metastasis (r=0.506; all <i>P</i><0.001) confirmed biological coherence. Performance gradients (malignancy > TNBC > LNM) reflect increasing microenvironment complexity.</p><p><strong>Conclusion: </strong>IPIO provides an integrated hemodynamic framework for both breast cancer diagnosis and risk stratification, with particular clinical utility for identifying triple-negative subtypes and metastatic potential. Its spatiotemporal profiling of vascular-peritumoral interactions represents a promising approach for noninvasive tumor characterization. Limitations include retrospective design and small TNBC subgroup; prospective validation is required.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"563533"},"PeriodicalIF":3.6,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13264308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Pegylated Liposomal Doxorubicin with Improved Overall Survival Compared with Epirubicin in Early-Stage Breast Cancer: A Population Based Study from Taiwan.","authors":"Yang-Chuan Chen, Min-Chi Cheng, Po-Huang Chen, Chi-Hsiang Chung, Wu-Chien Chien, Ming-Shen Dai, Jia-Hong Chen, Tzu-Chuan Huang","doi":"10.2147/BCTT.S595563","DOIUrl":"10.2147/BCTT.S595563","url":null,"abstract":"<p><strong>Purpose: </strong>Anthracycline-based regimens are a cornerstone of adjuvant therapy for early-stage breast cancer but are limited by cumulative cardiotoxicity. This study compared the effectiveness and cardiotoxicity of pegylated liposomal doxorubicin (Lipo-Dox) and epirubicin in women with early-stage, HER2-negative breast cancer using nationwide real-world data from Taiwan.</p><p><strong>Patients and methods: </strong>This population-based retrospective cohort study used Taiwan's National Health Insurance Research Database to identify adult women with stage I-III, HER2-negative breast cancer treated with adjuvant anthracycline-based chemotherapy between 2006 and 2018. Propensity score matching (1:1) was performed to balance baseline characteristics, resulting in 1050 matched patients with a median follow-up of 6.05 years. Overall survival (OS), disease-free survival (DFS), and cardiotoxicity were analyzed using Cox proportional hazards models and Kaplan-Meier methods.</p><p><strong>Results: </strong>Compared with epirubicin, Lipo-Dox was associated with significantly improved overall survival (adjusted hazard ratio 0.754, 95% CI 0.632-0.899; P < 0.001). Survival benefits were consistent across 3-year, 5-year, and full follow-up analyses and demonstrated a dose-dependent relationship. Kaplan-Meier curves confirmed superior overall survival in the Lipo-Dox group (log-rank P < 0.001). No significant differences were observed between the two groups in disease-free survival or clinically diagnosed cardiac events.</p><p><strong>Conclusion: </strong>In this nationwide propensity score-matched cohort, adjuvant Lipo-Dox was associated with sustained overall survival benefits without increased cardiotoxic risk compared with epirubicin. Lipo-Dox may represent a favorable anthracycline alternative, particularly for patients with cardiovascular comorbidities or elevated cardiotoxicity risk.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"595563"},"PeriodicalIF":3.6,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13242758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148203720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence-Driven Quantitative HER2 Scoring and Spatial Bystander Effect Modeling for ADC Response Stratification in HER2-Low Breast Cancer.","authors":"Jiayi Liu, Xinyue Zhang","doi":"10.2147/BCTT.S605985","DOIUrl":"10.2147/BCTT.S605985","url":null,"abstract":"<p><p>The rapid development of antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), has renewed interest in more refined assessment of low-end HER2 expression in breast cancer. However, substantial inter-observer variability in manual immunohistochemistry, especially around the IHC 0 versus 1+ boundary, remains a major challenge for consistent patient stratification. In this narrative review, we summarize emerging advances in computational pathology, including weakly supervised whole-slide image modeling and quantitative HER2 scoring approaches, and discuss their potential to improve interpretive consistency in this threshold-adjacent setting. We further examine the spatial rationale of the ADC bystander effect as a conceptual basis for integrating quantitative HER2 burden, heterogeneity, and spatial organization into response assessment. Rather than presenting these approaches as clinically established predictive tools, we argue that they should currently be viewed as exploratory and hypothesis-generating frameworks that warrant rigorous validation in outcome-linked, cross-platform, and multi-center studies. Overall, AI-assisted quantitative and spatial pathology may help refine biomarker development for ADC therapy in HER2-low breast cancer, but its clinical utility remains to be established through prospective and analytically robust validation.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"605985"},"PeriodicalIF":3.6,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13225144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148148299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative Complications Following Neoadjuvant Therapy Across Different Oncoplastic Breast Surgery Techniques: A Retrospective Comparative Study in Breast Cancer Patients.","authors":"Mahmut Onur Kulturoglu, Lutfi Dogan, Mehmet Ali Gulcelik","doi":"10.2147/BCTT.S607172","DOIUrl":"10.2147/BCTT.S607172","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant therapy (NAT) is increasingly used in breast cancer to downstage tumors and expand eligibility for breast-conserving approaches. NAT may also influence tissue vascularity and wound healing capacity, potentially affecting postoperative morbidity. Oncoplastic breast surgery (OBS) improves cosmetic outcomes while maintaining oncological safety; however, the impact of specific OBS techniques on postoperative complications after NAT remains unclear. In this context, postoperative complications are clinically important as they may lead to delayed initiation of adjuvant therapy, increased hospital stay, higher morbidity, and impaired cosmetic and quality-of-life outcomes. This study aimed to evaluate the associations between different OBS techniques and postoperative complications in patients undergoing surgery after NAT.</p><p><strong>Methods: </strong>This retrospective study included patients who underwent level II OBS after NAT between 2019 and 2025. Patients were categorized into five groups according to the surgical technique: racquet; vertical; radial fusiform incision; batwing-donut-Grisotti; and J-, L-, or V-shaped mammoplasties. The primary endpoint was comparison of complication rates among techniques. Secondary endpoints included identification of factors associated with complications. Complications were graded using the Clavien-Dindo classification, and overall morbidity was assessed using the Comprehensive Complication Index (CCI).</p><p><strong>Results: </strong>A total of 556 patients were analyzed. Racquet and vertical mammoplasties were associated with significantly larger resection volumes than the other techniques. These two techniques demonstrated significantly higher rates of overall and major complications, as well as wound dehiscence, surgical site infection, and seroma (p<0.05). Clavien-Dindo grades and CCI scores were also significantly higher in the racquet and vertical mammoplasty groups. Despite these differences, reoperation rates did not differ significantly between techniques.</p><p><strong>Conclusion: </strong>Postoperative complication rates were significantly influenced by the OBS technique chosen following NAT. Racquet and vertical mammoplasties were associated with higher morbidity, likely due to larger resection volumes, altered tissue perfusion, and more extensive tissue dissection. Individualized technique selection based on tumor characteristics, breast anatomy, and patient risk factors is essential to minimize complications while preserving oncological safety and aesthetic outcomes.</p>","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"18 ","pages":"607172"},"PeriodicalIF":3.6,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13222610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148142715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}